Clinical and epidemiological features of multiple myeloma patients from a low socio-economic region of Brazil

Minnicelli, Carolina; Rafael Maciel, James Farley; Hassan, Rocio; Ara├║jo Moura Lemos, Telma Maria
September 2015
Revista Brasileira de Hematologia e Hemoterapia;Sep/Oct2015, Vol. 37 Issue 5, p354
Academic Journal
Letter to the Editor
A letter to the editor is presented on the cohort study of the epidemiological and clinical features of patients with multiple myeloma (MM) in Brazil that belongs to the region with a low socio-economic condition.


Related Articles

  • A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Tedeschi, R; Kvarnung, M; Knekt, P; Schulz, T F; Szekely, L; Paoli, P De; Aromaa, A; Teppo, L; Dillner, J // British Journal of Cancer;1/1/2001, Vol. 84 Issue 1, p122 

    Presence of the Human Herpesvirus 8 (HHV8) genome has been reported in the bone marrow of multiple myeloma (MM) patients. So far, serological studies of HHV8 and MM have been inconsistent but have not included prospective epidemiological studies. We evaluated whether HHV8 infection is associated...

  • Regimen recaptured responses in heavily pretreated multiple myeloma.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p44 

    The article presents the results of a phase two study as of late October 2013, which showed that the combination of panobinostat, bortezomib and dexamethasone is effective in heavily pretreated patients with bortezomib-refractory multiple myeloma.

  • 12. Vaccination strategies in multiple myeloma.  // Hematology Journal;2003 Supplement, Vol. 4 Issue 1, pS267 

    The Hematology Journal (2003) 4, S267-S272. doi:10.1038/sj.thj.6200292

  • Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis. Kapoor, P.; Rajkumar, S. V.; Dispenzieri, A.; Gertz, M. A.; Lacy, M. Q.; Dingli, D.; Mikhael, J. R.; Roy, V.; Kyle, R. A.; Greipp, P. R.; Kumar, S.; Mandrekar, S. J. // Leukemia (08876924);Sep2011, Vol. 25 Issue 9, p1523 

    A correction to the article "Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis" that was published online on January 14, 2011 is presented.

  • Cytogenetic abnormalities found in multiple myeloma patients. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;09/25/97, Vol. 10 Issue 9, p28 

    States that cytogenetic abnormalities can be found in multiple myeloma patients. Reason for the occurrence of abnormalities; Types of common and nonrandom abnormalities; Prognosis of patients.

  • Multiple myeloma: Controlling pain, prolonging survival. Farrant, Catherine // RN;Jan87, Vol. 50 Issue 1, p38 

    Presents a case study that describes how treatment and skilled nursing care can help patients with multiple myeloma minimize complications and live more independently in the time they have left. Manifestations of the disease; Diagnosis and treatment procedures performed.

  • Cerebral toxoplasmosis in multiple myeloma. Theologides, Athanasios; Osterberg, Kenneth; Kennedy, B.J.; Theologides, A; Osterberg, K // Annals of Internal Medicine;May66, Vol. 64 Issue 5, p1071 

    Describes the occurrence of cerebral toxoplasmosis in a patient with controlled multiple myeloma. Result of postmortem examination; Information on localized cerebral toxoplasmosis; Relationship between toxoplasmosis and thyroid disease.

  • Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Shimoni, A; Smith, T L; Aleman, A; Weber, D; Dimopoulos, M; Anderlini, P; Andersson, B; Claxton, D; Ueno, N T; Khouri, I; Donato, M; Korbling, M; Alexanian, R; Champlin, R; Giralt, S // Bone Marrow Transplantation;4/15/2001, Vol. 27 Issue 8, p821 

    The study was designed to evaluate the efficacy and safety of an intensive, tri-alkylator conditioning regimen, consisting of thiotepa, busulfan and cyclophosphamide (TBC), prior to autologous hematopoietic cell transplantation in patients with multiple myeloma (MM) and to analyze factors...

  • Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Thieblemont, C; Dumontet, C; Saad, H; Roch, N; Bouafia, F; Arnaud, P; Hequet, O; Espinouse, D; Salles, G; Roy, P; Eljaafari-Corbin, A; du Manoir-Baumgarten, C; Coiffier, B // Bone Marrow Transplantation;12/1/2002, Vol. 30 Issue 11, p769 

    High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics